Global ETD Search

1	Re: Maud Rijnders, Ronald de Wit, Joost L. Boormans, Martijn P.J. Lolkema, Astrid A.M. van der Veldt. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. Eur Urol. 2017;72:411–23 Martinez Merizalde Balarezo, Nelson, Monroe Rivera, Mark, Tejada, Romina A. 03 1900 (has links) El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado. / “Cartas al editor” / Revisión por pares antineoplastic agent immune checkpoint inhibitor therapy immunomodulating agent unclassified drug
2	Fas signaling is involved in the control of hair follicle response to chemotherapy. Sharov, A.A., Siebenhaar, F., Sharova, T.Y., Botchkareva, Natalia V., Gilchrest, B.A., Botchkarev, Vladimir A. January 2004 (has links) No / Chemotherapeutic agents induce p53-dependent apoptosis in the hair follicle (HF) resulting in hair loss, a common side effect of cancer therapy. Here, we show that Fas as a p53 target plays important role in the HF response to cyclophosphamide. Specifically, we demonstrate that Fas is up-regulated in HF keratinocytes after cyclophosphamide treatment, Fas ligand-neutralizing antibody partially inhibits HF response to cyclophosphamide in wild-type mice, and Fas knockout mice show significant retardation of cyclophosphamide-induced HF involution associated with reduced Fas-associated death domain and caspase-8 expression. These data raise a possibility to explore blockade of Fas signaling as a part of complex local therapy for inhibiting keratinocyte apoptosis and hair loss induced by chemotherapy. Fas antigen Antineoplastic agent Treatment Chemotherapy Hair follicle Regulation(control) Signal transduction
3	Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells Pors, Klaus, Paniwnyk, Z., Patterson, Laurence H., Ruparelia, K.C., Hartley, J.A., Kelland, L.R. January 2004 (has links) No / Novel 1- and 1,4-substituted chloroethylaminoanthraquinones with DNA binding and alkylating properties along with their respective hydroxyethylaminoanthraquinone intermediates were synthesized. Selected chloroethylaminoanthraquinones were shown to cross-link DNA and alkylate guanines (at low nM concentration) with a preference for reaction sites containing 5'-PyG. A compound (Alchemix) with the bis-chloroethyl functionality confined to one side chain alkylated but did not cross-link DNA. All the 1,4-disubstituted chloroethylaminoanthraquinones were potently cytotoxic (nM IC50s) against cisplatin-resistant ovarian cancer cell lines. Platinum II Complexes Alkylating agent Organic chlorine compounds Diamine Aromatic amine Quinone Anthraquinone derivatives Chemical synthesis Ovary Human Cell line In vitro Cisplatin Tumor cell Resistance Cytotoxicity Antineoplastic agent Structure activity relation
4	Expression von SLC-Transportern in Melanomzelllinien und Charakterisierung von MATE1 und OCT1 in ihrer Funktion als Zytostatikatransporter / Expression of SLC transporters in melanoma cell lines and characterization of MATE1 and OCT1 in their function as transporters of antineoplastic agents Grottker, Julia 25 October 2011 (has links) No description available. 540 Chemie Chemistry MATE1 OCT1 Organische-Kationen-Transporter 1 SLC Solute-Carrier Chemotherapie Zytostatikum Melanom Transportprotein Chemoresistenz Zytostatikatra MATE1 OCT1 Organic-Cation-Transporter 1 SLC Solute Carrier chemotherapy antineoplastic agent malignant melanoma transport protein chemoresistance 35.70 44.37 44.33 SX000
5	Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells Teesdale-Spittle, P.H., Pors, Klaus, Brown, R., Patterson, Laurence H., Plumb, J.A. January 2005 (has links) No / A novel series of 1,4-disubstituted aminoanthraquinones were prepared by ipso-displacement of 1,4-difluoro-5,8-dihydroxyanthraquinones by hydroxylated piperidinyl- or pyrrolidinylalkyl-amino side chains. One aminoanthraquinone (13) was further derivatized to a chloropropyl-amino analogue by treatment with triphenylphosphine-carbon tetrachloride. The compounds were evaluated in the A2780 ovarian cancer cell line and its cisplatin-resistant variants (A2780/ cp70 and A2780/MCP1). The novel anthraquinones were shown to possess up to 5-fold increased potency against the cisplatin-resistant cells compared to the wild-type cells. Growth curve analysis of the hydroxyethylaminoanthraquinone 8 in the osteosarcoma cell line U-2 OS showed that the cell cycle is not frozen, rather there is a late cell cycle arrest consistent with the action of a DNA-damaging topoisomerase II inhibitor. Accumulative apoptotic events, using time lapse photography, indicate that 8 is capable of fully engaging cell cycle arrest pathways in G2 in the absence of early apoptotic commitment. 8 and its chloropropyl analogue 13 retained significant activity against human A2780/cp70 xenografted tumors in mice. Treatment resistance Transition metal Complexes Divalent metal Complexes Platinum II Complexes Malignant tumour Alkylating agent Vertebrata Mammalia Rodentia Cell line Chlorine Organic compounds Animal Ovary Tumour cell Human Alcohol Antineoplastic agent Mechanism of action Antimitotic Intraperitoneal administration Chemotherapy Cytotoxicity In vivo Pyrrolidine derivatives Piperidine derivatives Tricyclic compound Condensed benzenic compound Structure activity relation Diphenols Aromatic amine Ovarian cancer In vitro Chemical synthesis Cisplatin

1

Page generated in 0.1088 seconds